Japan

Reimbursed Care Access

Japan maintains a conservative, prohibition‑focused legal framework for classical psychedelic compounds (psilocybin, MDMA, DMT, 5‑MeO‑DMT, mescaline, ayahuasca, ibogaine and 2C‑X) — these are controlled under national drug control statutes and have no authorised medical use outside approved research. Ketamine is an established, licensed anesthetic and analgesic in Japan and is available via the medical system; psychiatric/off‑label use for depression is conducted as clinical care or research with limited reimbursement. Esketamine (the S‑enantiomer marketed internationally as SPRAVATO) has been the subject of clinical trials in Japan but there is no clear, publicly available PMDA/MHLW marketing authorisation and routine national reimbursement for esketamine is not established; other classical psychedelics are restricted to clinical trials only or are criminally controlled.